Evidence map›Paper›PMID 32039030›Full record

ArticleFrontiers in oncology2019

Case of Hereditary Papillary Renal Cell Carcinoma Type I in a Patient With a Germline

Dmitry S Mikhaylenko, Alexey V Klimov, Vsevolod B Matveev, Svetlana I Samoylova, Vladimir V Strelnikov, Dmitry V Zaletaev, Ludmila N Lubchenko, Boris Y Alekseev, Marina V Nemtsova

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Hereditary Renal Cancer Syndromes.Medical sciences (Basel, Switzerland) · 2024
    Review
  3. Review
  4. MET alterations in biphasic squamoid alveolar papillary renal cell carcinomas and clinicopathological features.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Dmitry S MikhaylenkoLaboratory of Medical Genetics, Institute of Molecular Medicine, Scientific Biotechnological Park of Biomedicine, Sechenov University, Moscow, Russia.
Alexey V KlimovDepartment of Urology, Institute of Clinical Oncology, N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.
Vsevolod B MatveevDepartment of Urology, Institute of Clinical Oncology, N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.
Svetlana I SamoylovaLaboratory of Medical Genetics, Institute of Molecular Medicine, Scientific Biotechnological Park of Biomedicine, Sechenov University, Moscow, Russia.
Vladimir V StrelnikovLaboratory of Epigenetics, Research Centre for Medical Genetics Named After Academician N. P. Bochkov, Moscow, Russia.
Dmitry V ZaletaevLaboratory of Medical Genetics, Institute of Molecular Medicine, Scientific Biotechnological Park of Biomedicine, Sechenov University, Moscow, Russia.
Ludmila N LubchenkoDepartment of Urology, Institute of Clinical Oncology, N. N. Blokhin National Medical Research Center of Oncology, Moscow, Russia.
Boris Y AlekseevLaboratory of Pathology and Molecular Genetics, N. Lopatkin Institute of Urology and Interventional Radiology - Branch of the National Medical Research Center of Radiology, Moscow, Russia.
Marina V NemtsovaLaboratory of Medical Genetics, Institute of Molecular Medicine, Scientific Biotechnological Park of Biomedicine, Sechenov University, Moscow, Russia.
National Medical Research Center of Cardiology · RUResearch Centre for Medical Genetics · RUSechenov University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary papillary renal carcinoma (HPRC) is a rare autosomal dominant disease characterized by the development of multiple papillary type I renal cell carcinomas. This hereditary kidney cancer form is caused by activating mutations in

Indexed as

germline mutationhereditary cancer syndromekidney cancerMET genepapillary renal cell carcinoma

Identifiers

PMID32039030
PMCPMC6985093
OpenAlexW3002163609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.